Cite
HARVARD Citation
Azim, H. et al. (2020). Understanding the benefits and challenges of first‐line cyclin‐dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women. Breast journal. 26 (4), pp. 630-642. [Online].